Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting

By K. Zhou, J. Strickler, Hui Chen. 2024

Subfields: Drug Discovery, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “2, normally restricted to the gastric mucosa, is exposed in malignant transformation and is currently under investigation in phase III trials with the monoclonal antibody zolbetuximab in gastric and gastroesophageal cancers [26].”